DK132894C - Analogifremgangsmade til fremstilling af 3-oxo-17alfa-acyloxyandrost-4-en-17beta-carboxylsyreestere - Google Patents

Analogifremgangsmade til fremstilling af 3-oxo-17alfa-acyloxyandrost-4-en-17beta-carboxylsyreestere

Info

Publication number
DK132894C
DK132894C DK29672*#A DK29672A DK132894C DK 132894 C DK132894 C DK 132894C DK 29672 A DK29672 A DK 29672A DK 132894 C DK132894 C DK 132894C
Authority
DK
Denmark
Prior art keywords
acyloxyandrost
17alfa
17beta
oxo
production
Prior art date
Application number
DK29672*#A
Other languages
English (en)
Other versions
DK132894B (da
Inventor
G H Phillipps
P J May
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of DK132894B publication Critical patent/DK132894B/da
Application granted granted Critical
Publication of DK132894C publication Critical patent/DK132894C/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
DK29672*#A 1971-01-20 1972-01-20 Analogifremgangsmade til fremstilling af 3-oxo-17alfa-acyloxyandrost-4-en-17beta-carboxylsyreestere DK132894C (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB278771A GB1384372A (en) 1971-01-20 1971-01-20 Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids

Publications (2)

Publication Number Publication Date
DK132894B DK132894B (da) 1976-02-23
DK132894C true DK132894C (da) 1976-07-26

Family

ID=9745890

Family Applications (1)

Application Number Title Priority Date Filing Date
DK29672*#A DK132894C (da) 1971-01-20 1972-01-20 Analogifremgangsmade til fremstilling af 3-oxo-17alfa-acyloxyandrost-4-en-17beta-carboxylsyreestere

Country Status (17)

Country Link
JP (1) JPS5611720B1 (da)
AU (1) AU473868B2 (da)
BE (1) BE778285A (da)
CA (1) CA1003820A (da)
CH (1) CH602786A5 (da)
DE (1) DE2202691A1 (da)
DK (1) DK132894C (da)
ES (1) ES399057A1 (da)
FR (1) FR2122539B1 (da)
GB (1) GB1384372A (da)
HK (1) HK34278A (da)
IE (1) IE36000B1 (da)
IL (1) IL38589A (da)
NL (1) NL172511C (da)
NO (1) NO137321C (da)
SE (1) SE383522B (da)
ZA (1) ZA72401B (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2365102C2 (de) * 1973-12-21 1982-12-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue Pregnansäure-Derivate
DE2444618C2 (de) * 1974-09-16 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue Pregnan-21-säure-Derivate
DE2319479C2 (de) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
SE427276B (sv) * 1975-04-03 1983-03-21 Hoffmann La Roche Forfarande for framstellning av d-homosteroider
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
IT1114534B (it) * 1978-02-08 1986-01-27 Glaxo Group Ltd Steroide anti-infiammatorio della serie dell'androstano composizioni che lo contengono e procedimento per produrlo
CA1138857A (en) * 1979-01-24 1983-01-04 Leo Alig D-homosteroids
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
OA12394A (en) 2000-08-05 2004-07-09 Glaxo Group Ltd 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent.
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
EP2039700A2 (en) 2001-04-30 2009-03-25 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
ATE454154T1 (de) 2003-06-19 2010-01-15 Nicholas S Bodor Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung
ATE369138T1 (de) 2003-06-19 2007-08-15 Nicholas S Bodor Verstärkung der aktivität und/oder wirkdauer von ausgewählten entzündungshemmenden steroiden
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
EP1841780B1 (en) 2005-01-10 2011-07-27 Glaxo Group Limited Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
DE102010029877A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
DE102010029875A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids

Also Published As

Publication number Publication date
NO137321C (no) 1978-02-08
DE2202691A1 (de) 1972-08-03
NL172511C (nl) 1983-09-16
ZA72401B (en) 1973-09-26
GB1384372A (en) 1975-02-19
DK132894B (da) 1976-02-23
BE778285A (fr) 1972-07-20
JPS5611720B1 (da) 1981-03-16
IE36000B1 (en) 1976-07-21
NL172511B (nl) 1983-04-18
CH602786A5 (da) 1978-08-15
IL38589A (en) 1976-06-30
ES399057A1 (es) 1974-11-01
AU473868B2 (en) 1976-07-08
IL38589A0 (en) 1972-03-28
HK34278A (en) 1978-07-07
NO137321B (no) 1977-10-31
IE36000L (en) 1972-07-20
CA1003820A (en) 1977-01-18
SE383522B (sv) 1976-03-15
NL7200818A (da) 1972-07-24
AU3811072A (en) 1973-07-26
FR2122539B1 (da) 1975-11-28
FR2122539A1 (da) 1972-09-01

Similar Documents

Publication Publication Date Title
DK132894C (da) Analogifremgangsmade til fremstilling af 3-oxo-17alfa-acyloxyandrost-4-en-17beta-carboxylsyreestere
DK133158C (da) Analogifremgangsmade til fremstilling af 3-oxo-17alfa-acyloxyandrost-4-en-17beta-carboxylsyreestere
DK143271C (da) Analogifremgangsmaade til fremstilling af 4-phenoxy-phenoxyalkancarboxylsyrederivater
DK134600C (da) Fremgangsmade til fremstilling af usymmetriske 1,4-dihydropyridindicarboxylsyreestere
DK139361C (da) Analogifremgangsmaade til fremstilling af 17alfa-hydroxy-3,20-dioxo-4-pregnen-21-syrer
NO147917C (no) Fremgangsmaate for fremstilling av 3-metyl-delta3-cefem-4-karboksylsyre-forbindelser
SE399707B (sv) Analogiforfarande for framstellning av olefinarylketoner
SE382452B (sv) Analogiforfarande for framstellning av substituerade insuliner
DK136612C (da) Analogifremgangsmaade til fremstilling af 3,20-dioxo-4-pregnen-21-syrederivater
DK130959B (da) Analogifremgangsmåde til fremstilling af benzamidoacetohydroxamsyrer.
NO137587C (no) Fremgangsmaate for fremstilling av svovelsyre
DK551178A (da) Analogifremgangsmaade til fremstilling af prostaglandin-analoge
IT946458B (it) Procedimento per la fabbricazione di basamenti per piante
DK136034C (da) Analogifremgangsmade til fremstilling af sulfamoylpyrimidiner
DK133297C (da) Analogifremgangsmade til fremstilling af 6-halogen-6-cyklohexylindan-1-karbohydroxamsyre
DK140896B (da) Fremgangsmåde til fremstilling af en 7-D-alfa-aminoacetamidocephalosporin-4-carboxylsyre.
DK133277B (da) Fremgangsmade til fremstilling af transchrysanthemsyre
SE410311B (sv) Utgangsforening for framstellning av substituerade 3-amino-prop-1-ener
DK137192B (da) Analogifremgangsmåde til fremstilling af cephalosporansyrederivater.
DK138447C (da) Fremgangsmaade til fremstilling af hexahydro-indan-4-carboxylsyreestere
DK140942B (da) Fremgangsmåde til fremstilling af 7-aminocephalosporansyre.
SE7514792L (sv) Forfarande for framstellning av urokinas
DK153472C (da) Fremgangsmaade til fremstilling af alfa-anilinocarboxylsyrenitriler
DK132223C (da) Analogifremgangsmade til fremstilling af benzensulfonamidopyrimidiner
SE383744B (sv) Forfarande for framstellning av kromon-2-karbonsyror